Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NUVB vs LYEL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
LYEL Captures Overall Composite Edge (35.1 SELL vs 61.0 BUY), While NUVB Leads 4–1 on Growth & Valuation Pillars
LYEL Overall Winner
6-Pillar Tally: NUVB 4 – 1 LYEL (1 Tie)
Matrix Metrics: NUVB 6 – 2 LYEL
As of Nov 20, 2026, Lyell Immunopharma, Inc. (LYEL) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (35.1/100 SELL vs. 61.0/100 BUY) after splitting the core matrix 2–6 (led by Options & Positioning), while NUVB wins 4–1 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus LYEL at $13.80 (N/M Forward P/E, -1341693.4% operating margin).
- Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. LYEL 35.1/100 SELL), LYEL captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1341693.4% vs. -61.2% operating margin) and revenue trajectory (-80.0% vs. +242.6% YoY).
- Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile LYEL trades in a Neutral technical trend (SURGE options phase, RSI 55.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NUVB vs LYEL
NUVB
Nuvation Bio Inc.
$3.80
-0.26% 1D
Market Cap
$1.3B
TTM Revenue
$202M
Forward P/E
N/M
Beta / 30D Vol
1.52β · 55% Vol
Unified Composite Score
61.0
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
LYEL
Head-to-Head Winner
Lyell Immunopharma, Inc. Common Stock
$13.80
+1.62% 1D
Market Cap
$434.8M
TTM Revenue
$15,000
Forward P/E
N/M
Beta / 30D Vol
1.62β · 163% Vol
Unified Composite Score
35.1
SELL
Tech 15.0
Fund 39.0
Flow 67.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (NUVB 4 – 1 LYEL)
1. Valuation Multiples
NUVB
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
7.4x
N/M
2. Growth & Scale
NUVB
Revenue Growth (YoY)
+242.6%
-80.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$202M
$15,000
Market Cap
$1.3B
$434.8M
3. Profitability & Quality
NUVB
Gross Margin
85.8%
100.0%
Operating Margin
-61.2%
-1341693.4%
Net Profit Margin
-67.4%
0.0%
Return on Equity (ROE)
-49.1%
-97.8%
4. Balance Sheet & Cash Flow
NUVB
Cash Generation (TTM)
-$108M
-$140M
Cash Flow Margin
-53.6%
N/A
Net Cash / Leverage
$146M Net Debt (1.32x D/E)
$58M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
LYEL
Options Structure Phase
BREAKDOWN
SURGE
Current IV / %ile
65.2% (26th %ile)
258.5% (58th %ile)
Put/Call OI Skew
0.24x (Call-Skewed)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NUVB (6) vs LYEL (2)| Institutional Metric | NUVB | LYEL | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.3B | $434.8M | NUVB | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +242.6% | -80.0% | NUVB | |
| Operating Margin (TTM) | -61.2% | -1341693.4% | NUVB | |
| Net Profit Margin | -67.4% | 0.0% | LYEL | |
| Return on Equity (ROE) | -49.1% | -97.8% | NUVB | |
| 52-Week Range Position | 2% ($4–$10) | 18% ($7–$45) | LYEL | |
| Beta / 30D Volatility | 1.52β · 55% Vol | 1.62β · 163% Vol | NUVB | |
| Unified Institutional Score | 61.0 / 100 (BUY) | 35.1 / 100 (SELL) | NUVB | |
| Trailing 12M Revenue (USD) | $202M | $15,000 | Scale | |
| Gross Profit Margin (TTM) | 85.8% | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 7.4x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$108M ($146M Net Debt (1.32x D/E)) | -$140M ($58M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
LYEL +66.27 pp
3M Horizon
LYEL +37.41 pp
6M Horizon
NUVB +1.47 pp
1Y Horizon
LYEL +26.99 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NUVB Revenue | LYEL Revenue | NUVB Op. Margin | LYEL Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $0M | N/A | -15538.7% | LYEL |
| FY2020 | N/A | $10M | N/A | -2732.6% | LYEL |
| FY2021 | N/A | $10M | N/A | -2016.7% | LYEL |
| FY2022 | N/A | $80M | N/A | -220.9% | LYEL |
| FY2023 | N/A | $0M | N/A | -190006.2% | LYEL |
| FY2024 | $10M | $0M | -7527.3% | -588123.0% | NUVB |
| FY2025 | $60M | $0M | -338.7% | -748344.4% | NUVB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NUVB
BREAKDOWN
Current IV
65.2%
IV Percentile
26th %ile
Put/Call OI Skew
0.24x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
LYEL
SURGE
Current IV
258.5%
IV Percentile
58th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact LYEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NUVB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
LYEL Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ NUVB vs LYEL Key Questions & Quantitative Answers
As of Nov 20, 2026, Lyell Immunopharma, Inc. (LYEL) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (35.1/100 SELL vs. 61.0/100 BUY) after splitting the core matrix 2–6 (led by Options & Positioning), while NUVB wins 4–1 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus LYEL at $13.80 (N/M Forward P/E, -1341693.4% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. LYEL 35.1/100 SELL), LYEL captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1341693.4% vs. -61.2% operating margin) and revenue trajectory (-80.0% vs. +242.6% YoY). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile LYEL trades in a Neutral technical trend (SURGE options phase, RSI 55.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with LYEL at -80.0% YoY revenue growth and +0.0% YoY earnings growth on $15,000 TTM revenue (100.0% gross margin, -1341693.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), NUVB cumulative revenue shifted +500.0% while LYEL shifted +700.0%. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYEL.
NUVB screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas LYEL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus LYEL (-97.8% ROE) capital efficiency.
In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, LYEL carries 258.5% implied volatility (58th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.62β · 163% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
LYEL vs NUVB · Reverse Pair
NUVB vs TSHA
· Sector Peer
NUVB vs STOK
· Sector Peer
NUVB vs OLMA
· Sector Peer
LYEL vs GLUE
· Sector Peer
LYEL vs ERAS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem